Psychosocial Oncology

D (calcitriol) on transitional cell carcinoma of the bladder in vitro and in vivo. J Urol. 2001;165:253-258. 30. Hermann GG, Andersen CB. Transitional cell carcinoma express vitamin D receptors. Scand J Urol Nephrol. 1997;31:161166. 31. Fujioka T, Hasegawa M, Ishikura K, et al. Inhibition of tumor growth and angiogenesis by vitamin D3 agents in murine renal cell carcinoma. J Urol. 1998;160:247-251. 32. Simboli-Campbell M, Narvaez CJ, Tenniswood M, Welsh J. 1,25dihydroxyvitamin D3 induces morphological and biochemical markers of apoptosis in MCF-7 breast cancer cells. J Steroid Biochem Mol Biol. 1996;58:367-376. 33. Harris NM, Crook TJ, Dyer JP, et al. Intravesical meglumine gamma-linolenic acid in superficial bladder cancer: an efficacy study. Eur Urol. 2002;42:39-42. 34. Boik J. Natural Compounds in Cancer Therapy. Princeton, Minn: Oregon Medical Press; 2001. 35. Clark LC, Combs GF, Turnbull BW, et al. Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin. JAMA. 1996;276:1957-1963. 36. Spivak MY. On the use of phytoeides of garlic and onion for the treatment of tumorous patients [in Russian]. Vopr Onkol. 1962;8:93-96. 37. Jones E. Cancer: Its Causes, Symptoms, and Treatment. Wenatchee, Wash: Healing Mountain; 1911, reprinted 2001. 38. Farnsworth NR. The phytochemistry and biological activity of Catharnathus lanceus (Apocyanaceae). In: Swain T, ed. Plants in the Development of Modern Medicine. Cambridge, Mass: Harvard University Press; 1972:279-302. 39. Noble RL, Beer CT, Cutts JH. Role of chance observations in chemotherapy: Vinca rosea. Ann N Y Acad Sci. 1958;76:882-894. 40. Ojima I, Bounaud PY, Takeuchi C, Pera P, Bernacki RJ. New taxanes as highly efficient reversal agents for multidrug resistance in cancer cells. Bioorg Med Chem Lett. 1998;8:189-194. 41. Chattopadhyay SK, Kumar TR, Maulik PR, et al. Absolute configuration and anticancer activity of taxiresinol and related lignans of Taxus wallichiana. Bioorg Med Chem. 2003;11:49454948. 42. Chen WM, Zhang PL, Wu B, Zheng QT. Studies on the chemical constituents of Taxus yunnanensis [in Chinese]. Yao Xue Xue Bao. 1991;26:747-754. 43. Zhou DC, Zittoun R, Marie JP. Homoharringtonine: an effective new natural product in cancer chemotherapy. Bull Cancer. 1995;82:987-995. 44. Chang HM, But PPH, eds. Pharmacology and Applications of Chinese Materia Medica. Vol 1. Hackensack, NJ: World Scientific; 1986. 45. Kuo YH, Lin CH, Hwang SY, et al. A novel cytotoxic C-methylated biflavone from the stem of Cephalotaxus wilsoniana. Chem Pharm Bull (Tokyo). 2000;48:440-441. 46. Bocar M, Jossang A, Bodo B. New alkaloids from Cephalotaxus fortunei. J Nat Prod. 2003;66:152-154. 47. Yarnell E. The botanical roots of pharmaceutical discovery. Altern Complement Ther. 2000:6(3):125-8. 48. Redman BG, Esper P, Pan Q, et al. Phase II trial of tetrathiomolybdate in patients with advanced kidney cancer. Clin Cancer Res. 2003;9:1656-1672. 49. Brewer GJ, Merajver SD. Cancer therapy with tetrathiomolybdate: antiangiogenesis by lowering body copper—a review. Integr Cancer Ther. 2002;1:327-337. 50. Meng XL, Riordan NH, Casciari JJ, et al. Effects of a high molecular mass Convolvulus arvensis extract on tumor growth and angiogenesis. P R Health Sci J. 2002;21:323-328. 51. Pienta KJ, Naik H, Akhtah A, et al. Inhibition of spontaneous metastasis in a rat prostate cancer model by oral administration of modified citrus pectin. J Natl Cancer Inst. 1995;87:348-353. 52. Platt D, Raz A. Modulation of the lung cell colonization of B16F1 melanoma cells by citrus pectin. J Natl Cancer Inst. 1992;18:438-442. 53. Theodorescu D, Laderoute KR, Calaoagan JM, Guilding KM. Inhibition of human bladder cancer cell motility by genistein is dependent on epidermal growth factor receptor but not p21ras gene expression. Int J Cancer. 1998;78:775-782. 54. Kaufman PB, Duke JA, Brielmann H, Boik J, Hoyt JE. A comparative survey of leguminous plants as sources of the isoflavones genistein and daidzein: implications for human nutrition and health. J Altern Complement Med. 1997;3:7-12. 55. Silverman DT, Hartge P, Morrison AS, Devesa SS. Epidemiology of bladder cancer. Hematol Oncol Clin North Am. 1992;6:130. 56. Wan XS, Lu LJ, Anderson KE, Ware JH, Kennedy AR. Urinary excretion of Bowman-Birk inhibitor in humans after soy consumption as determined by a monoclonal antibody-based immunoassay. Cancer Epidemiol Biomarkers Prev. 2000;9:741-747. 57. Armstrong WB, Kennedy AR, Wan XS, et al. Clinical modulation of oral leukoplakia and protease activity by Bowman-Birk inhibitor concentrate in a phase IIa chemoprevention trial. Clin Cancer Res. 2000;6:4684-4691. 58. Rural Development Administration. Bowman-Birk protease inhibitor content in soybeans and soybean products. Korea Soybean Digest. 2003;17(1):61-68. Available at: http:// www.fftc. agnet.org/library/article/rh2003007b.html. Accessed December 8, 2004.